Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 625-631

  Hamadani, Mehdi ^a   Saber, Wael ^b   Ahn, Kwang Woo ^b   Carreras, Jeanette ^b   Cairo, Mitchell S ^c   Fenske, Timothy S ^b   Gale, Robert Peter ^d   Gibson, John ^e   Hale, Gregory A ^f   Hari, Parameswaran N ^b   Hsu, Jack W ^g   Inwards, David J ^h   Kamble, Rammurti T ⁱ   Klein, Anderas ^j   Maharaj, Dipnarine ^k   Marks, David I ^l   Rizzieri, David A ^m   Savani, Bipin N ⁿ   Schouten, Harry C ^o   Waller, Edmund K ^p   Wirk, Baldeep ^g   Lazarus, Hillard M ^q   more..

^a WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h MAYO CLINIC ROCHESTER   (United States)

ⁱ CENTER FOR CELL AND GENE THERAPY   (United States)

^j TUFTS MEDICAL CENTER   (United States)

^k Bethesda Health City   (United States)

^l BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁿ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^o MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^p EMORY UNIVERSITY HOSPITAL   (United States)

^q UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

more..

Author keywords

Chemorefractory disease; Graft versus host disease; Myeloablative conditioning; Non Hodgkin lymphoma; Reduced intensity conditioning

Indexed keywords

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; NONRELAPSE MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RISK; T CELL DEPLETION;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERNATIONAL COOPERATION; LONGITUDINAL STUDIES; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84875481784     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.01.009     Document Type: Article

References (31)

1. Zhou Y., Wang H., Fang W., et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008, 113:791-798.
2. Romaguera J.E., Fayad L.E., Feng L., et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010, 150:200-208.
3. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677-2684.
4. Damon L.E., Johnson J.L., Niedzwiecki D., et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009, 27:6101-6108.
5. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
6. Kenkre V.P., Long W.L., Eickhoff J.C., et al. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma 2011, 52:1675-1680.
7. Kluin-Nelemans J.C., Hoster E., Walewski J., et al. R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-α: outcome of the first randomized trial for elderly patients with mantle cell lymphoma. Blood 2011, 118:439.
8. Herrmann A., Hoster E., Zwingers T., et al. Improvement of overall survival in advanced-stage mantle cell lymphoma. J Clin Oncol 2009, 27:511-518.
9. Zucca E., Roggero E., Pinotti G., et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995, 6:257-262.
10. Till B.G., Gooley T.A., Crawford N., et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008, 49:1062-1073.
11. Vandenberghe E., Ruiz de Elvira C., Loberiza F.R., et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003, 120:793-800.
12. Vose J.M., Bierman P.J., Weisenburger D.D., et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2000, 6:640-645.
13. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
14. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22:2172-2176.
15. Le Gouill S., Milpied N., Buzyn A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008, 26:2264-2271.
16. Thomson K.J., Morris E.C., Bloor A., et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:426-432.
17. van Kampen R.J., Canals C., Schouten H.C., et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011, 29:1342-1348.
18. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100:4310-4316.
19. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004, 104:3535-3542.
20. Corradini P., Dodero A., Farina L., et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007, 21:2316-2323.
21. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
22. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
23. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
24. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
25. Gooley T.A., Leisenring W., Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
26. Clark T.G., Altman D.G., De Stavola B.L. Quantification of the completeness of follow-up. Lancet 2002, 359:1309-1310.
27. Tam C.S., Bassett R., Ledesma C., et al. Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.
28. Cook G., Smith G.M., Kirkland K., et al. Outcome following reduced-intensity allogeneic stem cell transplantation (RIC alloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2010, 16:1419-1427.
29. Le Gouill S., Kroger N., Dhedin N., et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012, 10:2695-2703.
30. Gopal A.K., Guthrie K.A., Rajendran J., et al. (9)(0)Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011, 118:1132-1139.
31. Bethge W.A., Lange T., Meisner C., et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood 2010, 116:1795-1802.